Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

The Antiretroviral Therapy Cohort Collaboration
The Lancet HIV, Vol. 4, No. 8, e349–e356, August 2017

8 pp. 590 kB

Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. The authors examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013. They conclude that even in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity. Prognostic models and life expectancy estimates should be updated to account for these improvements.

(Visited 4 times, 1 visits today)
This entry was posted in Essential Medicines, General, HIV - AIDS - STI. Bookmark the permalink.